Protein Degraders: From Discovery To Development

Targeted protein degradation has emerged as a transformative approach in drug discovery by enabling the selective elimination of disease-associated proteins using the ubiquitin-proteasome system. Modalities like protein degraders and molecular glues offer therapeutic solutions for previously "undruggable" targets and mechanisms to overcome resistance to traditional small molecule inhibitors. Given this complexity, innovative and tailored strategies are needed at every step of the process.

Curia offers integrated discovery platforms and end-to-end support, spanning from ligand identification and lead optimization to IND-enabling studies. This support includes an expert medicinal chemistry team with a decade of experience, which utilizes a library of Linker-Ligase pieces and Computer Aided Drug Design (CADD). Additionally, Curia provides advanced structural biology, including crystallization and high-resolution structures by protein crystallography or cryo-EM. The process is supported by advanced screening technologies such as high content imaging, ASMS, and HiBIT, with automated workflows designed to accelerate discovery.